دورية أكاديمية

Molecular magnetic resonance imaging of liver inflammation using an oxidatively activated probe.

التفاصيل البيبلوغرافية
العنوان: Molecular magnetic resonance imaging of liver inflammation using an oxidatively activated probe.
المؤلفون: Jordan VC; Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sojoodi M; Harvard Medical School, Boston, MA, USA.; Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Boston, MA, USA., Shroff S; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Pagan PG; Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Barrett SC; Harvard Medical School, Boston, MA, USA.; Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Boston, MA, USA., Wellen J; Bristol Meyers Squibb, Cambridge, MA, USA., Tanabe KK; Harvard Medical School, Boston, MA, USA.; Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Boston, MA, USA., Chung RT; Harvard Medical School, Boston, MA, USA.; Gastroenterology Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Caravan P; Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Gale EM; Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
المصدر: JHEP reports : innovation in hepatology [JHEP Rep] 2023 Jul 18; Vol. 5 (10), pp. 100850. Date of Electronic Publication: 2023 Jul 18 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101761237 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5559 (Electronic) Linking ISSN: 25895559 NLM ISO Abbreviation: JHEP Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2019]-
مستخلص: Background & Aims: Many liver diseases are driven by inflammation, but imaging to non-invasively diagnose and quantify liver inflammation has been underdeveloped. The inflammatory liver microenvironment is aberrantly oxidising owing in part to reactive oxygen species generated by myeloid leucocytes. We hypothesised that magnetic resonance imaging using the oxidatively activated probe Fe-PyC3A will provide a non-invasive biomarker of liver inflammation.
Methods: A mouse model of drug-induced liver injury was generated through intraperitoneal injection of a hepatoxic dose of acetaminophen. A mouse model of steatohepatitis was generated via a choline-deficient, l-amino acid defined high-fat diet (CDAHFD). Images were acquired dynamically before and after intravenous injection of Fe-PyC3A. The contrast agent gadoterate meglumine was used as a non-oxidatively activated negative control probe in mice fed CDAHFD. The (post-pre) Fe-PyC3A injection change in liver vs. muscle contrast-to-noise ratio (ΔCNR) recorded 2 min post-injection was correlated with liver function test values, histologic scoring assigned using the NASH Clinical Research Network criteria, and intrahepatic myeloid leucocyte composition determined by flow cytometry.
Results: For mice receiving i.p. injections of acetaminophen, intrahepatic neutrophil composition correlated poorly with liver test values but positively and significantly with ΔCNR (r = 0.64, p <0.0001). For mice fed CDAHFD, ΔCNR generated by Fe-PyC3A in the left lobe was significantly greater in mice meeting histologic criteria strongly associated with a diagnosis NASH compared to mice where histology was consistent with likely non-NASH ( p  = 0.0001), whereas no differential effect was observed using gadoterate meglumine. In mice fed CDAHFD, ΔCNR did not correlate strongly with fractional composition of any specific myeloid cell subpopulation as determined by flow cytometry.
Conclusions: Magnetic resonance imaging using Fe-PyC3A merits further evaluation as a non-invasive biomarker for liver inflammation.
Impact and Implications: Non-invasive tests to diagnose and measure liver inflammation are underdeveloped. Inflammatory cells such as neutrophils release reactive oxygen species which creates an inflammatory liver microenvironment that can drive chemical oxidation. We recently invented a new class of magnetic resonance imaging probe that is made visible to the scanner only after chemical oxidation. Here, we demonstrate how this imaging technology could be applied as a non-invasive biomarker for liver inflammation.
Competing Interests: EMG holds equity in, and receives consulting income from Reveal Pharmaceuticals, and receives consulting income from Collagen Medical, LLC. PC holds equity in, and receives consulting income from Collagen Medical LLC, holds equity in Reveal Pharmaceuticals, and has research funding from Takeda, Pliant Therapeutics, and Janssen. Please refer to the accompanying ICMJE disclosure forms for further details.
(© 2023 The Authors.)
References: Magn Reson Med. 2004 Jan;51(1):35-45. (PMID: 14705043)
J Am Chem Soc. 2015 Dec 16;137(49):15548-57. (PMID: 26588204)
J Hepatol. 2019 Jun;70(6):1222-1261. (PMID: 30926241)
J Clin Transl Res. 2017 Feb;3(Suppl 1):157-169. (PMID: 28670625)
US Gastroenterol Hepatol Rev. 2010 Jan 1;6:73-80. (PMID: 21874146)
Radiology. 2020 Jan;294(1):98-107. (PMID: 31743083)
Adv Hepatol. 2014 Nov 30;2014:. (PMID: 26436133)
J Hepatol. 2009 Aug;51(2):371-9. (PMID: 19501928)
Hepatology. 2011 Jul;54(1):344-53. (PMID: 21520200)
Hepatology. 2017 Mar;65(3):907-919. (PMID: 27880989)
Hepatol Int. 2016 Jan;10(1):1-98. (PMID: 26563120)
Hepatology. 2005 Jun;41(6):1313-21. (PMID: 15915461)
Radiology. 2018 Mar;286(3):865-872. (PMID: 29117483)
J Hepatol. 2019 Jan;70(1):151-171. (PMID: 30266282)
Eur Radiol. 2003 Jun;13(6):1266-76. (PMID: 12764641)
Hepatology. 1996 Aug;24(2):289-93. (PMID: 8690394)
Hepatology. 2018 Jul;68(1):349-360. (PMID: 29222917)
J Hepatol. 2021 Oct;75(4):810-819. (PMID: 34126105)
Hepatol Commun. 2019 Nov 05;4(2):185-192. (PMID: 32025604)
J Hepatol. 1995 Jun;22(6):696-9. (PMID: 7560864)
J Am Chem Soc. 2019 Apr 10;141(14):5916-5925. (PMID: 30874437)
Magn Reson Med. 2008 Nov;60(5):1122-34. (PMID: 18956464)
Invest Radiol. 2021 Apr 1;56(4):261-270. (PMID: 33136686)
Radiology. 2015 Jul;276(1):228-32. (PMID: 25942417)
Am J Respir Crit Care Med. 2002 Dec 15;166(12 Pt 2):S4-8. (PMID: 12471082)
Curr Hepatol Rep. 2016 Jun;15(2):86-95. (PMID: 27795938)
Abdom Radiol (NY). 2016 Sep;41(9):1744-50. (PMID: 27108126)
Gut. 2010 Feb;59(2):258-66. (PMID: 19919948)
Invest Radiol. 2019 Nov;54(11):697-703. (PMID: 31356382)
World J Hepatol. 2018 Jan 27;10(1):1-7. (PMID: 29399273)
Am J Gastroenterol. 2007 Apr;102(4):780-8. (PMID: 17222323)
Int J Exp Pathol. 2013 Apr;94(2):93-103. (PMID: 23305254)
Clin Liver Dis. 2020 Feb;24(1):89-106. (PMID: 31753253)
Hepatology. 2020 Feb;71(2):510-521. (PMID: 30582669)
Mod Pathol. 2017 May;30(5):773-783. (PMID: 28106105)
Hepatology. 2008 Jul;48(1):169-76. (PMID: 18537184)
PLoS Biol. 2020 Jul 14;18(7):e3000411. (PMID: 32663221)
AJR Am J Roentgenol. 2014 Sep;203(3):643-8. (PMID: 25148170)
Mol Pharm. 2008 Jul-Aug;5(4):496-504. (PMID: 18611037)
J Am Soc Nephrol. 2006 Sep;17(9):2359-62. (PMID: 16885403)
Radiology. 2022 Feb;302(2):270-273. (PMID: 34783590)
Radiology. 2017 Aug;284(2):390-400. (PMID: 28358240)
J Hepatol. 2017 Aug;67(2):370-398. (PMID: 28427875)
Hepatology. 1981 Sep-Oct;1(5):431-5. (PMID: 7308988)
AJR Am J Roentgenol. 2015 Mar;204(3):W302-13. (PMID: 25714316)
Gastroenterology. 2016 Mar;150(3):626-637.e7. (PMID: 26677985)
Radiology. 2016 Mar;278(3):782-91. (PMID: 26348104)
Invest Radiol. 2020 Apr;55(4):209-216. (PMID: 31895219)
Histopathology. 2012 Jan;60(2):236-48. (PMID: 21668470)
J Clin Invest. 2017 Jan 3;127(1):55-64. (PMID: 28045404)
معلومات مُعتمدة: K25 HL128899 United States HL NHLBI NIH HHS; R01 DK120663 United States DK NIDDK NIH HHS
فهرسة مساهمة: Keywords: Drug-induced liver injury; Reactive oxygen species; Steatohepatitis
تواريخ الأحداث: Date Created: 20231011 Latest Revision: 20240515
رمز التحديث: 20240515
مُعرف محوري في PubMed: PMC10561122
DOI: 10.1016/j.jhepr.2023.100850
PMID: 37818152
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-5559
DOI:10.1016/j.jhepr.2023.100850